These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

584 related items for PubMed ID: 17582067

  • 1. Injectable paromomycin for Visceral leishmaniasis in India.
    Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK.
    N Engl J Med; 2007 Jun 21; 356(25):2571-81. PubMed ID: 17582067
    [Abstract] [Full Text] [Related]

  • 2. Short-course paromomycin treatment of visceral leishmaniasis in India: 14-day vs 21-day treatment.
    Sundar S, Agrawal N, Arora R, Agarwal D, Rai M, Chakravarty J.
    Clin Infect Dis; 2009 Sep 15; 49(6):914-8. PubMed ID: 19663597
    [Abstract] [Full Text] [Related]

  • 3. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.
    Sundar S, Sinha PK, Rai M, Verma DK, Nawin K, Alam S, Chakravarty J, Vaillant M, Verma N, Pandey K, Kumari P, Lal CS, Arora R, Sharma B, Ellis S, Strub-Wourgaft N, Balasegaram M, Olliaro P, Das P, Modabber F.
    Lancet; 2011 Feb 05; 377(9764):477-86. PubMed ID: 21255828
    [Abstract] [Full Text] [Related]

  • 4. Single-dose liposomal amphotericin B for visceral leishmaniasis in India.
    Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW.
    N Engl J Med; 2010 Feb 11; 362(6):504-12. PubMed ID: 20147716
    [Abstract] [Full Text] [Related]

  • 5. Amphotericin B treatment for Indian visceral leishmaniasis: response to 15 daily versus alternate-day infusions.
    Sundar S, Chakravarty J, Rai VK, Agrawal N, Singh SP, Chauhan V, Murray HW.
    Clin Infect Dis; 2007 Sep 01; 45(5):556-61. PubMed ID: 17682988
    [Abstract] [Full Text] [Related]

  • 6. Oral miltefosine for Indian visceral leishmaniasis.
    Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, Junge K, Bryceson A, Berman J.
    N Engl J Med; 2002 Nov 28; 347(22):1739-46. PubMed ID: 12456849
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries.
    Berman JD, Badaro R, Thakur CP, Wasunna KM, Behbehani K, Davidson R, Kuzoe F, Pang L, Weerasuriya K, Bryceson AD.
    Bull World Health Organ; 1998 Nov 28; 76(1):25-32. PubMed ID: 9615494
    [Abstract] [Full Text] [Related]

  • 8. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study.
    Sundar S, Jha TK, Thakur CP, Mishra M, Singh VP, Buffels R.
    Clin Infect Dis; 2003 Sep 15; 37(6):800-4. PubMed ID: 12955641
    [Abstract] [Full Text] [Related]

  • 9. Magnitude of unresponsiveness to sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar.
    Das VN, Ranjan A, Bimal S, Siddique NA, Pandey K, Kumar N, Verma N, Singh VP, Sinha PK, Bhattacharya SK.
    Natl Med J India; 2005 Sep 15; 18(3):131-3. PubMed ID: 16130613
    [Abstract] [Full Text] [Related]

  • 10. Observations on amphotericin B treatment of kala-azar given in a rural set up in Bihar, India.
    Thakur CP, Ahmed S.
    Indian J Med Res; 2001 Jan 15; 113():14-8. PubMed ID: 11280166
    [Abstract] [Full Text] [Related]

  • 11. Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine.
    Sangraula H, Sharma KK, Rijal S, Dwivedi S, Koirala S.
    J Assoc Physicians India; 2003 Jul 15; 51():686-90. PubMed ID: 14621038
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Anthropometrically derived dosing and drug costing calculations for treating visceral leishmaniasis in Bihar, India.
    Olliaro P, Sundar S.
    Trop Med Int Health; 2009 Jan 15; 14(1):88-92. PubMed ID: 19121150
    [Abstract] [Full Text] [Related]

  • 14. New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine.
    Sundar S, Rai M, Chakravarty J, Agarwal D, Agrawal N, Vaillant M, Olliaro P, Murray HW.
    Clin Infect Dis; 2008 Oct 15; 47(8):1000-6. PubMed ID: 18781879
    [Abstract] [Full Text] [Related]

  • 15. Comparison of treatment regimens of kala-azar based on culture & sensitivity of amastigotes to sodium antimony gluconate.
    Thakur CP, Thakur S, Narayan S, Sinha A.
    Indian J Med Res; 2008 Jun 15; 127(6):582-8. PubMed ID: 18765878
    [Abstract] [Full Text] [Related]

  • 16. Treatment of visceral leishmaniasis in 2010: direction from Bihar State, India.
    Murray HW.
    Future Microbiol; 2010 Sep 15; 5(9):1301-3. PubMed ID: 20860475
    [No Abstract] [Full Text] [Related]

  • 17. Amphotericin B therapy in children with visceral leishmaniasis: daily vs. alternate day, a randomized trial.
    Singh UK, Prasad R, Jaiswal BP, Singh PK, Thakur CP.
    J Trop Pediatr; 2010 Oct 15; 56(5):321-4. PubMed ID: 20065047
    [Abstract] [Full Text] [Related]

  • 18. Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh.
    Rahman R, Goyal V, Haque R, Jamil K, Faiz A, Samad R, Ellis S, Balasegaram M, Boer MD, Rijal S, Strub-Wourgaft N, Alves F, Alvar J, Sharma B.
    PLoS Negl Trop Dis; 2017 May 15; 11(5):e0005635. PubMed ID: 28558062
    [Abstract] [Full Text] [Related]

  • 19. Amphotericin B in resistant kala-azar in Bihar.
    Thakur CP, Sinha GP, Pandey AK, Barat D, Sinha PK.
    Natl Med J India; 1993 May 15; 6(2):57-60. PubMed ID: 8477209
    [Abstract] [Full Text] [Related]

  • 20. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations.
    Sundar S, Mehta H, Suresh AV, Singh SP, Rai M, Murray HW.
    Clin Infect Dis; 2004 Feb 01; 38(3):377-83. PubMed ID: 14727208
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.